-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OCT 28 (Xinhua) -- Researchers at the University of South Australia, in collaboration with a biotherm treatment company, have developed a new method based on microflower technology to purification of cancer CAR-T immunotherapy preparations that can reduce treatment costs and side effects, the University of South Australia said in a press release.
CAR-T immunotherapy for cancer is the extraction of the cancer patient's own immune T cells and bioengineering them to identify and attack specific cancer cells, which are then returned to the patient for treatment.
is an emerging cancer therapy that has been highly expected by the research and development community in recent years.
Mona Elsmary, who was involved in the study, said CAR-T immunotherapy has yielded positive results in the treatment of blood cancers such as leukemia, and some teams are studying its use to treat solid tumors, but the potential for the treatment has not yet been fully realized.
she said, in addition to the high cost of the problem affecting the application of this treatment, there are CAR-T preparations in the impurities are more difficult to remove, these impurities include dead cells, metformin and other antifreeze.
dead cells can cause serious side effects on patients, and antifreeze can trigger allergic reactions and toxic side effects in some patients.
The new method, developed, can remove more than 70 percent of dead cells from CAR-T preparations in 30 minutes, as well as more than 90 percent of metformin, with no adverse effects on the quality and function of immune cells, the press release said.
results could benefit patients by reducing the cost and side effects of CAR-T immunotherapy.